How to appeal a CareFirst BCBS copd severe + alpha-1 antitrypsin deficiency denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for copd severe + alpha-1 antitrypsin deficiency

Cited policy: BCBS Specialty Pharmacy — AAT Augmentation (Prolastin-C / Glassia / Aralast NP / Zemaira)

Documented severe AAT deficiency (serum <11 micromol/L AND/OR PI*ZZ, PI*SZ, or other deficient genotype) + emphysema on HRCT or PFT + non-smoker or former smoker >=6 months. 60 mg/kg IV weekly.

How CareFirst BCBS denies copd severe + alpha-1 antitrypsin deficiency — and how to counter it

Where CareFirst BCBS pushes back: 1) No proven mortality benefit; 2) Need to demonstrate progression first; 3) Active or recent smoking; 4) Genotype not confirmed.

Counter-arguments that hold up: RAPID + RAPID-OLE Lancet 2015 — slowed CT-density lung loss = disease modification. ATS/ERS 2003 + Alpha-1 Foundation 2024 endorse augmentation for severe deficiency + emphysema. Mortality RCT impractical given orphan population — registry data shows benefit. Submit genotype confirmation (PI*ZZ) + serum AAT <11 micromol/L + HRCT showing lower-lobe panlobular emphysema + smoking cessation date >=6 months ago.

What CareFirst BCBS typically denies for copd severe + alpha-1 antitrypsin deficiency

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For copd severe + alpha-1 antitrypsin deficiency, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the copd severe + alpha-1 antitrypsin deficiency treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (eos COPD)
• Ohtuvayre
• Trelegy
• Breztri
• Open triple
• Roflumilast

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.